Alkermes/Cephalon Plan Vivitrol Launch In Q2 Following "Approvable" Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alkermes and Cephalon are preparing a second quarter launch of Vivitrol, a once-monthly naltrexone injection for the treatment of alcohol dependence, after receiving an "approvable" letter from FDA.
You may also be interested in...
Alkermes Vivitrol "complete response"
Alkermes' alcoholism treatment Vivitrol (extended-release naltrexone injection) could be approved as early as April if FDA accepts the firm's response to a Dec. 28, 2005 "approvable" letter as a Class 1 response. The response, announced Feb. 17, includes some additional data but no additional clinical studies. The approvable letter requested preclinical pharmacokinetic data to support reference to existing oral naltrexone preclinical data via Vivitrol's 505(b)(2) NDA (1Pharmaceutical Approvals Monthly January 2006, p. 28)…
Vivitrex 90-day extension
FDA's user fee deadline for Cephalon/Alkermes' once-monthly injectable naltrexone formulation Vivitrex is Dec. 30 following a 90-day extension, the firms announce Sept. 20. The extension stems from a recent response being reclassified as a major amendment. Vivitrex is receiving a priority review for treatment of alcoholism (1Pharmaceutical Approvals Monthly June 2005, In Brief)...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011